CRDL

Cardiol Therapeutics Inc. Class A Common Shares (CRDL) | Rumor.io

Cardiol Therapeutics

CRDL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,203

Bullish sentiment (50-day avg)90%

Price to earnings ratio-4.35

Market capitalization205.4M

Earnings per share-0.24

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-33.8M

Social

What share of all stock conversation is about CRDL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 23

Cardiol Therapeutics Inc. ($CRDL) has achieved the Phase III MAVERIC enrollment target ahead of schedule, and the steering committee recommends expanding the trial to up to 150 patients after a blinded review showed lower-than-expected recurrence events across both arms combined.
The expansion of the trial preserves statistical power for a robust readout, but pushes the topline from Q1 2027 to mid-2027; the primary endpoint is the time to the first new recurrence, matching the only FDA-approved recurrent pericarditis therapy's pivotal design.
Cardiol has strengthened its balance sheet with roughly $31M in gross proceeds, guided a runway beyond the expected Q1 2027 MAVERIC readout, and has room to reach the catalyst, which could lead to a binary repricing of the company's trials.

Generated by AI

Sentiment

Of the messages about CRDL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	93.94% +1.08	92.08% +2.73	91.99% +3.79
Bearish	0%	6.06% -1.08	7.92% -2.73	8.01% -3.79

Bullish· Aug 26

A strong cash runway and de-risked Phase 3 MAVERIC trial have been cited as reasons to be bullish on $CRDL, with a target price of $11.
The company's chart is in breakout mode, with major catalysts ahead, and Barchart has issued a 100% Buy Signal for $CRDL.
A new position has been started in $CRDL, and the stock is showing a strong start out of the gate, with accumulations looking healthy and someone making monster buys.

Bearish· Dec 1

The company's Phase III program has not shown the same level of success as its Phase II study, and the CEO's leadership has been called into question.
The company's stock price has been declining, and some investors are calling for a delisting, citing the CEO's salary and the company's lack of meaningful investment.
The company's marketing efforts have been criticized for being overly reliant on promotional videos from individuals in Mumbai, and some investors believe that the company is prioritizing the CEO's salary over shareholder interests.

Generated by AI

Topics

Of the messages about CRDL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	37.59%	2.24%
Announcements	—	100%	62.41%	9.51%
Analysts	—	0%	0%	44.44%
Controversies	—	0%	0%	0.24%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	43.56%

May 7

Cardiol Therapeutics' Phase II MAvERIC study results have been accepted for publication in the Journal of the American Heart Association, demonstrating rapid and sustained reductions in pericarditis pain and inflammation with CardiolRx.
The pivotal Phase III MAVERIC trial has surpassed 75% enrollment, with strong enrollment momentum and validation for the science and pipeline ahead.
The publication highlights clinical findings that treatment with CardiolRx may represent a paradigm shift in the treatment of patients with recurrent pericarditis, further validating the company's pipeline and pipeline ahead.

Generated by AI

Community

Of the messages about CRDL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	37.5%	88.39%	69.55%	31.12%
Newcomers	62.5%	11.61%	30.45%	68.88%

Regulars· Sep 23

The MAVERIC study has reached its original enrollment target of 110 patients ahead of schedule, with the steering committee recommending expansion to 150 patients after a blinded review showed lower-than-expected recurrence events across both arms combined.
The expansion of the Phase III trial preserves the statistical power for a robust readout, but pushes the topline from Q1 2027 to mid-2027, with the primary endpoint remaining the time to first new recurrence.
The decision to expand the trial is seen as a positive development, with analysts and investors expressing confidence in a positive outcome, and one analyst reiterating a BUY rating and 12-month PT of $10.

Newcomers· Aug 26

The newcomer is confident in the company's long-term potential, citing understanding of medicine and the value of the stock.
The newcomer believes the stock is gearing up for Phase III and is an easy one to hold onto, with a strong start out of the gate.
The newcomer is optimistic about the stock's chart and is seeing major catalysts ahead, with a 100% buy signal from Barchart.

Generated by AI

News

Cardiol expands phase III trial enrollment to 150 patients

7d agoInvesting.com

Cardiol Therapeutics at H.C. Wainwright conference: trial nears finish

15d agoInvesting.com

Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL)

Cardiol Therapeutics is a binary, catalyst-driven biotech, with its investment case hinging on CardiolRx’s Phase III MAVERIC trial. See more on CRDL stock here.

17d agoSeeking Alpha

Cardiol Therapeutics files $150 million shelf prospectus

19d agoInvesting.com

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada, together with a corresponding registration statement on Form F-10 (the "Registration Statement") with the

20d agoYahoo Finance

Stocks in play: Cardiol Therapeutics Inc.

Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.

20d agoThe Globe and Mail

Also Discussed

Investors talking about CRDL also mention

#	Name	Attention
1	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
2	NeuroSense Therapeutics Ltd.NRSN	0%0
3	Gossamer Bio Inc.GOSS	0%+0
4	Coeptis Therapeutics, Inc.COEP	0%0
5	Orion Digital Corp.MOGO	0%0
6	Leverage Shares 2X Long GLXY Daily ETFGLGG	0%0
7	BREA - Brera Holdings PLC Class B Ordinary Shares	——
8	InnovAge Holding Corp.INNV	0%0
9	MDNA - Medicenna Therapeutics Corp.	——
10	IONM - Assure Holdings Corp.	——

Cardiol Therapeutics Inc. Class A Common Shares

Healthcare
Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s current work centers on CardiolRx, a pharmaceutically manufactured oral cannabidiol formulation in clinical development for cardiovascular indications, including inflammatory heart conditions. Cardiol Therapeutics also advances related formulations and programs aimed at addressing the biological pathways involved in cardiac inflammation and fibrosis. Its business is concentrated in the biotechnology and pharmaceutical segments of the healthcare market, where it contributes to the development of specialized therapies for serious heart disorders. Based in Oakville, Ontario, Cardiol Therapeutics is positioned as a research-driven company with a narrow therapeutic focus on heart disease treatment.

Website

Location

2265 Upper Middle Road East

Oakville, ON, L6H 0G5

Canada

Social

What share of all stock conversation is about CRDL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Sep 23

Cardiol Therapeutics Inc. ($CRDL) has achieved the Phase III MAVERIC enrollment target ahead of schedule, and the steering committee recommends expanding the trial to up to 150 patients after a blinded review showed lower-than-expected recurrence events across both arms combined.
The expansion of the trial preserves statistical power for a robust readout, but pushes the topline from Q1 2027 to mid-2027; the primary endpoint is the time to the first new recurrence, matching the only FDA-approved recurrent pericarditis therapy's pivotal design.
Cardiol has strengthened its balance sheet with roughly $31M in gross proceeds, guided a runway beyond the expected Q1 2027 MAVERIC readout, and has room to reach the catalyst, which could lead to a binary repricing of the company's trials.

Generated by AI

Sentiment

Of the messages about CRDL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	93.94% +1.08	92.08% +2.73	91.99% +3.79
Bearish	0%	6.06% -1.08	7.92% -2.73	8.01% -3.79

Bullish· Aug 26

A strong cash runway and de-risked Phase 3 MAVERIC trial have been cited as reasons to be bullish on $CRDL, with a target price of $11.
The company's chart is in breakout mode, with major catalysts ahead, and Barchart has issued a 100% Buy Signal for $CRDL.
A new position has been started in $CRDL, and the stock is showing a strong start out of the gate, with accumulations looking healthy and someone making monster buys.

Bearish· Dec 1

The company's Phase III program has not shown the same level of success as its Phase II study, and the CEO's leadership has been called into question.
The company's stock price has been declining, and some investors are calling for a delisting, citing the CEO's salary and the company's lack of meaningful investment.
The company's marketing efforts have been criticized for being overly reliant on promotional videos from individuals in Mumbai, and some investors believe that the company is prioritizing the CEO's salary over shareholder interests.

Generated by AI

Topics

Of the messages about CRDL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	37.59%	2.24%
Announcements	—	100%	62.41%	9.51%
Analysts	—	0%	0%	44.44%
Controversies	—	0%	0%	0.24%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	43.56%

May 7

Cardiol Therapeutics' Phase II MAvERIC study results have been accepted for publication in the Journal of the American Heart Association, demonstrating rapid and sustained reductions in pericarditis pain and inflammation with CardiolRx.
The pivotal Phase III MAVERIC trial has surpassed 75% enrollment, with strong enrollment momentum and validation for the science and pipeline ahead.
The publication highlights clinical findings that treatment with CardiolRx may represent a paradigm shift in the treatment of patients with recurrent pericarditis, further validating the company's pipeline and pipeline ahead.

Generated by AI

Community

Of the messages about CRDL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	37.5%	88.39%	69.55%	31.12%
Newcomers	62.5%	11.61%	30.45%	68.88%

Regulars· Sep 23

The MAVERIC study has reached its original enrollment target of 110 patients ahead of schedule, with the steering committee recommending expansion to 150 patients after a blinded review showed lower-than-expected recurrence events across both arms combined.
The expansion of the Phase III trial preserves the statistical power for a robust readout, but pushes the topline from Q1 2027 to mid-2027, with the primary endpoint remaining the time to first new recurrence.
The decision to expand the trial is seen as a positive development, with analysts and investors expressing confidence in a positive outcome, and one analyst reiterating a BUY rating and 12-month PT of $10.

Newcomers· Aug 26

The newcomer is confident in the company's long-term potential, citing understanding of medicine and the value of the stock.
The newcomer believes the stock is gearing up for Phase III and is an easy one to hold onto, with a strong start out of the gate.
The newcomer is optimistic about the stock's chart and is seeing major catalysts ahead, with a 100% buy signal from Barchart.

Generated by AI

Cardiol Therapeutics

Social

Sep 23

Bullish· Aug 26

Bearish· Dec 1

May 7

Regulars· Sep 23

Newcomers· Aug 26

Cardiol expands phase III trial enrollment to 150 patients

Cardiol Therapeutics at H.C. Wainwright conference: trial nears finish

Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL)

Cardiol Therapeutics files $150 million shelf prospectus

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Stocks in play: Cardiol Therapeutics Inc.

Also Discussed

Cardiol Therapeutics Inc. Class A Common Shares

Company Information

Location

Cardiol expands phase III trial enrollment to 150 patients

Cardiol Therapeutics at H.C. Wainwright conference: trial nears finish

Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL)

Cardiol Therapeutics files $150 million shelf prospectus

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Stocks in play: Cardiol Therapeutics Inc.

Also Discussed

Social

Sep 23

Bullish· Aug 26

Bearish· Dec 1

May 7

Regulars· Sep 23

Newcomers· Aug 26